BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bunglawala F, Rajoli RKR, Mirochnick M, Owen A, Siccardi M. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. J Antimicrob Chemother 2020;75:640-7. [PMID: 31860112 DOI: 10.1093/jac/dkz506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Rabie H, Lishman J, Frigati LJ. Moving forward with dolutegravir in children weighing less than 20 kg. The Lancet HIV 2022;9:e301-2. [DOI: 10.1016/s2352-3018(22)00062-5] [Reference Citation Analysis]
2 Cottura N, Howarth A, Rajoli RKR, Siccardi M. The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development. J Clin Pharmacol 2020;60 Suppl 1:S77-97. [PMID: 33205431 DOI: 10.1002/jcph.1715] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Chaphekar N, Dodeja P, Shaik IH, Caritis S, Venkataramanan R. Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models. Front Pediatr 2021;9:733823. [PMID: 34805038 DOI: 10.3389/fped.2021.733823] [Reference Citation Analysis]
4 Camacho-Gonzalez AF, Palumbo P. HIV in Neonates and Infants. Clin Perinatol 2021;48:275-92. [PMID: 34030814 DOI: 10.1016/j.clp.2021.03.004] [Reference Citation Analysis]
5 Montanha MC, Fabrega F, Howarth A, Cottura N, Kinvig H, Bunglawala F, Lloyd A, Denti P, Waitt C, Siccardi M. Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. Clin Pharmacokinet 2021. [PMID: 34635995 DOI: 10.1007/s40262-021-01067-1] [Reference Citation Analysis]
6 Liu XI, Momper JD, Rakhmanina NY, Green DJ, Burckart GJ, Cressey TR, Mirochnick M, Best BM, van den Anker JN, Dallmann A. Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. Clin Pharmacokinet 2021;60:795-809. [PMID: 33527213 DOI: 10.1007/s40262-020-00977-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Khan S, Albayaty M, Bush J, Cheriyan J, Cromie A, Koch A, Hammond M, Mair S, Lorch U, Stringer S, Taubel J, Hardman TC. The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges. Front Pharmacol 2020;11:580560. [PMID: 33364955 DOI: 10.3389/fphar.2020.580560] [Reference Citation Analysis]
8 Wang K, Jiang K, Wei X, Li Y, Wang T, Song Y. Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development. AAPS PharmSciTech 2021;22:208. [PMID: 34312742 DOI: 10.1208/s12249-021-02076-w] [Reference Citation Analysis]